Dinoprostone
- PMID: 30000698
- Bookshelf ID: NBK501637
Dinoprostone
Excerpt
Dinoprostone (prostaglandin E2) has not been measured in human milk after exogenous administration, but it is a normal component of breastmilk in small amounts where it may help protect the infant's gastrointestinal tract.
Use of vaginal dinoprostone to induce labor appears to have a negative effect on breastfeeding. Given orally in the first few days postpartum, dinoprostone can suppress lactation. Whether postpartum vaginal or endocervical administration suppresses lactation is not known, but it should probably not be used postpartum in mothers who wish to breastfeed. By one month postpartum, the drug appears not to suppress lactation.
References
-
- Neu J, Wu-Wang CY, Measel CP, et al. Prostaglandin concentrations in human milk. Am J Clin Nutr 1988;47:649-52. - PubMed
-
- Hawkes JS, Bryan DL, James MJ, et al. Cytokines (Il-1beta, Il-6, TNF-alpha, TGF-beta1, and TGF-beta2) and prostaglandin E2 in human milk during the first three months postpartum. Pediatr Res 1999;46:194-9. - PubMed
-
- Le Deist F, De Saint-Basile G, Angeles-Cano E, et al. Prostaglandin E2 and plasminogen activators in human milk and their secretion by milk macrophages. Am J Reprod Immunol Microbiol 1986;11:6-10. - PubMed
-
- Shimizu T, Yamashiro Y, Yabuta K. Prostaglandin E1, E2, and F2 alpha in human milk and plasma. Biol Neonate 1992;61:222-5. - PubMed
Publication types
LinkOut - more resources
Full Text Sources